Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options (Tables)

v3.20.2
Stock-Based Compensation, Restricted Stock and Stock Options (Tables)
3 Months Ended
Jun. 30, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of stock based compensation expenses
    Three months ended
June 30,
 
    2020     2019  
Research and development expenses   $ 1,152,341     $ 258,908  
Selling, general and administrative expenses     6,926,882       838,035  
Total stock-based compensation   $ 8,079,223     $ 1,096,943  
Schedule of restricted stock awards

    Number of
Shares
    Weighted Average
Grant-Date
Fair Value
 
Unvested at March 31, 2020     3,750,009     $ 0.82  
Granted     4,000,000     $ 1.38  
Vested     (4,749,997 )   $ 1.28  
Unvested at June 30, 2020 (unaudited)     3,000,012     $ 0.82  
Schedule of of stock options granted
    June 30,
2020
 
    (Unaudited)  
Dividend yield     0 %
Expected price volatility     50.0 %
Risk free interest rate     0.16% - 0.44 %
Expected term     5-6 years  
Schedule of stock options

    Shares
Underlying
Options
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
 Term (Years)
    Aggregate
Intrinsic
Value
 
Outstanding at March 31, 2020     5,813,500     $ 0.18       8.2     $ 4,243,610  
Granted     8,236,667     $ 0.75       9.1       -  
Outstanding at June 30, 2020 (unaudited)     14,050,167     $ 0.51       8.6     $ 6,840,042  
                                 
Exercisable at June 30, 2020 (unaudited)     14,050,167     $ 0.51       8.6     $ 6,840,042